Scorpius Holdings Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Scorpius Holdings de 75.2% y 50.1% respectivamente, mientras que el BPA crecerá en un 98.3% al año.

Información clave

75.2%

Tasa de crecimiento de los beneficios

98.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	50.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	30 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:SCPX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	16	-9	N/A	N/A	1
12/31/2024	8	-22	N/A	N/A	1
9/30/2024	10	-30	-22	-22	N/A
6/30/2024	10	-30	-21	-21	N/A
3/31/2024	10	-32	-22	-22	N/A
12/31/2023	7	-40	-34	-32	N/A
9/30/2023	2	-51	-41	-38	N/A
6/30/2023	2	-50	-44	-26	N/A
3/31/2023	1	-45	-30	-9	N/A
12/31/2022	0	-41	-26	-6	N/A
9/30/2022	1	-38	-29	-9	N/A
6/30/2022	1	-36	-30	-29	N/A
3/31/2022	2	-36	-46	-43	N/A
12/31/2021	2	-35	-40	-38	N/A
9/30/2021	2	-28	-35	-33	N/A
6/30/2021	2	-29	-27	-23	N/A
3/31/2021	3	-27	-22	-21	N/A
12/31/2020	3	-26	-22	-22	N/A
9/30/2020	4	-23	-16	-16	N/A
6/30/2020	4	-20	-15	-15	N/A
3/31/2020	3	-21	-15	-14	N/A
12/31/2019	3	-20	-13	-13	N/A
9/30/2019	3	-22	-19	-19	N/A
6/30/2019	5	-19	-18	-18	N/A
3/31/2019	6	-18	-22	-22	N/A
12/31/2018	6	-16	-22	-22	N/A
9/30/2018	4	-14	-13	-13	N/A
6/30/2018	3	-13	N/A	-13	N/A
3/31/2018	2	-12	N/A	-7	N/A
12/31/2017	2	-12	N/A	-6	N/A
9/30/2017	1	-12	N/A	-12	N/A
6/30/2017	1	-11	N/A	-10	N/A
3/31/2017	0	-11	N/A	-12	N/A
12/31/2016	0	-13	N/A	-14	N/A
9/30/2016	0	-16	N/A	-16	N/A
6/30/2016	N/A	-19	N/A	-18	N/A
3/31/2016	N/A	-21	N/A	-18	N/A
12/31/2015	N/A	-20	N/A	-17	N/A
9/30/2015	N/A	-17	N/A	-15	N/A
6/30/2015	N/A	-15	N/A	-14	N/A
3/31/2015	N/A	-13	N/A	-12	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	N/A	-10	N/A	-9	N/A
6/30/2014	N/A	-10	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SCPX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que SCPX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que SCPX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (50.1% al año) de SCPX crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (50.1% al año) de SCPX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SCPX se prevé que sea elevada dentro de 3 años.

Scorpius Holdings Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Price target decreased to US$21.83

Price target decreased to US$23.83

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Price target decreased to US$21.83

Price target decreased to US$23.83

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold US$205k worth of stock

Consensus forecasts updated

Consensus revenue estimates fall to US$1.98m

Heat Biologics names Anthony Manning as chief scientific advisor

Price target decreased to US$24.67

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Heat Biologics EPS misses by $0.01, misses on revenue

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

New 90-day high: US$8.76

Price target lowered to US$27.30

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento